Corrigendum to “Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II” (Molecular Genetics and Metabolism (2022) 137(1–2) (92–103), (S1096719222003833), (10.1016/j.ymgme.2022.07.016))

on behalf of the SHP609-302 study group

Pediatrics

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Corrigendum to “Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II” (Molecular Genetics and Metabolism (2022) 137(1–2) (92–103), (S1096719222003833), (10.1016/j.ymgme.2022.07.016))'. Together they form a unique fingerprint.

Sort by
Weight
Alphabetically

Corrigendum to “Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II” (Molecular Genetics and Metabolism (2022) 137(1–2) (92–103), (S1096719222003833), (10.1016/j.ymgme.2022.07.016))

Fingerprint

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Nursing and Health Professions